2022³â ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è Çмú´ëȸ(2ÀÏÂ÷) : 2022-04-15±³À°ÀÏÀÚ : 2022-04-15
±³À°Àå¼Ò : °æÁÖ ¶óÇÑ ¼¿·ºÆ® È£ÅÚ ÄÁº¥¼ÇȦ
±³À°ÁÖÁ¦ :
2022³â ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è Çмú´ëȸ(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ(18.7 ¸íĪº¯°æ ´ëÇÑÈÇпä¹ýÇÐȸ)
´ã´çÀÚ : ¹Ú½ÂÀ±
¿¬¶ôó : 02-557-1755
À̸ÞÀÏ :
ksc@ksac.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
°æ»óºÏµµ±³À°½Ã°£ : 7 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 140,000¿ø
ºñ°í Á¤È¸¿ø Àü°øÀÇ 5¸¸¿ø,ÀüÀÓÀÇ 8¸¸¿ø,Àü¹®ÀÇ ¹× ÀÏ¹Ý 10¸¸¿ø ºñȸ¿ø Àü°øÀÇ 7¸¸¿ø,ÀüÀÓÀÇ 10¸¸¿ø, Àü¹®ÀÇ ¹× ÀÏ¹Ý 12¸¸¿ø ÇöÀåµî·Ï Àü°øÀÇ 9¸¸¿ø, ÀüÀÓÀÇ 12¸¸¿ø, Àü¹®ÀÇ ¹× ÀÏ¹Ý 14¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-15 ¾ÆÁ¦³ª+¸®°ÖȦ 07:30~08:00 CMV infection vs. CMV diseases - optimal prophylaxis & treatment ÀÌ»ó¿À(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-15 ¾ÆÁ¦³ª+¸®°ÖȦ 08:00~08:30 Immune modulating agent - infection risk and prophylaxis ¼À¯ºó(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 08:30~09:20 Redefining Peace of Mind in HIV care ÇãÁß¿¬(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04-15 º£°¡È¦ 08:30~09:20 Therapeutic role of new ¥â-lactam/¥â-lactamase inhibitors in patient with MDR Gram-negative pathogens. À±¿µ°æ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 09:20~09:50 Host-based PK/PD for antibiotic therapy: sepsis and immunocompromised hosts À̵¿°Ç(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 09:50~10:20 Antibiotic agent PK/PD: therapeutic drug monitoring for optimized antibiotic dosing À̽Âȯ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 10:20~10:50 Antimicrobial synergism for multi-drug resistant Gram-negative bacterial infection °Ã¶ÀÎ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 11:10~11:40 Antimicrobial stewardship in Korea: current status and the way forward ±èºÀ¿µ(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 11:40~12:10 Korean core element of antimicrobial stewardship program: prerequisites for activation ±Ç±âÅÂ(°æºÏÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 13:00~13:50 The challenges of current diagnostic and treatment of IFI: The Value of CRESEMBA/VFEND/ERAXIS ¾ÈÁø¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 16:00~16:30 Oral antivirals and monoclonal antibody for COVID-19 ¹Ú¿Ï¹ü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 16:30~17:00 Clinical usefulness and optimal use of immune modulating agents in COVID-19 ÃÖÁØ¿ë(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-15 ÄÁº¥¼ÇȦ 17:00~17:30 Antibiotic treatment for COVID-19 pneumonia: pros and cons ÃßÀºÁÖ(¼øõÇâÀÇ´ë)